COVID-19 infection COVID-19 infection SAR-CoV-2 viral load Emerging Disease Molnupiravir Infectious Disease
Conditions
Interventions
Benchalokawichian, oral administration, 3 capsule qid for 5 days
and Junleela, oral administration, 3 capsule qid for 5 days
,Molnupiravir (200 mg capsules), oral administration, 4 capsules every 1
Experimental Drug,Active Comparator Drug
Thai Traditional Herbs,Standard Treatment
Sponsors
Srinakharinwirot University
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: age 20-60 years old, with a positive result for COVID-19 through an Antigen Test Kit (ATK) and experiencing at least one symptom of upper respiratory tract infection(URI) not exceeding 5 days.
Exclusion criteria
Exclusion criteria: critical conditions requiring hospitalization, abnormal findings in chest X-rays, uncontrolled chronic diseases, severe allergies to herbal medicines, pregnant or lactating women, immunocompromised host, stage 3 or higher chronic kidney disease (CKD), cerebrovascular diseases, obesity, liver diseases, and a lymphocyte count of less than 1,000 cells/microliter.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral quantity at 0, 6 days after the intervention viral PCR,Interleukin-6 at 0, 6 days after the intervention the laboratory method by which Interleukin-6 is measured | — |
Secondary
| Measure | Time frame |
|---|---|
| safety at 0, 6 days after the intervention CBC, creatinine, AST, ALT,COVID-19 signs and symptoms at 0, 6 days after the intervention subjective data | — |
Countries
Thailand
Contacts
Public ContactVilaval Termklinchan
Panyananthaphikkhu Chonprathan Medical Center
Outcome results
None listed